银屑病关节炎患者达到低疾病活动度后停用TNF抑制剂可获得持续临床获益
基于CORRONA注册队列的观察性研究,评估银屑病关节炎(PsA)患者在低疾病活动度(LDA)时停用TNF抑制剂(TNFi)后临床获益的持续时间。302例患者停药时平均CDAI 3.9,中位获益丧失时间为29.2个月,55.1%患者末次随访仍有持续获益;停药时较高疾病活动度(CDAI≥3.2 vs <3.2)和吸烟与获益丧失风险增加相关。
要点
- PsA患者达到LDA后停用TNFi,中位临床获益持续29.2个月。
- 停药时CDAI≥3.2较<3.2的获益丧失风险HR为1.43(p=0.32)。
- 吸烟者获益丧失风险增加,HR为1.78(p=0.027)。
核心结论
- 达到低疾病活动度的PsA患者停用TNFi后可能维持临床获益,中位获益丧失时间为29.2个月。
研究设计与样本
- 观察性队列研究,纳入CORRONA注册中5945例PsA患者,其中302例在LDA时停用TNFi(n=325次停药)且有随访数据。
- LDA定义为CDAI评分≤10且医生对皮肤银屑病总体评估(PGA)≤20/100。
- 采用Kaplan-Meier法估计临床获益持续时间。
主要发现
- 停药时平均PsA病程9.8年,平均CDAI为3.9,平均TNFi使用时间1.5年。
- 52.6%患者停用的是第一种TNFi。
- 179例(55.1%)患者在上次门诊随访时仍有持续临床获益。
- 停药时疾病活动度较高(CDAI≥3.2 vs <3.2)者获益丧失风险HR为1.43(p=0.32)。
- 吸烟者获益丧失风险HR为1.78(p=0.027)。
关键数值与推荐
- LDA标准为CDAI≤10且PGA皮肤银屑病≤20/100。
- 停药时CDAI≥3.2 vs <3.2的获益丧失HR为1.43(p=0.32)。
- 吸烟者获益丧失HR为1.78(p=0.027)。
临床怎么用
- 对于达到LDA的PsA患者,可考虑停用TNFi,但需告知中位获益持续时间约29.2个月。
- 停药时疾病活动度较高(CDAI≥3.2)和吸烟可能与获益丧失风险增加相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the duration of clinical benefit among patients with psoriatic arthritis (PsA) discontinuing tumour necrosis factor inhibitor (TNFi) therapy while in low disease activity (LDA), and to identify patient characteristics associated with prolonged clinical benefit. METHODS: We performed an observational cohort study assessing patients with PsA from the Consortium of Rheumatology Researchers of North America (CORRONA) registry who had discontinued TNFi after achieving LDA, defined as clinical disease activity index (CDAI) score ≤10 and physician's global assessment (PGA) of skin psoriasis ≤20/100. Kaplan-Meier method was used to estimate the duration of clinical benefit. RESULTS: Of the 5945 patients with PsA in CORRONA, 302 patients had discontinued TNFi (n=325) while in LDA and had follow-up data available. At time of discontinuation, mean PsA duration was 9.8 years, mean CDAI was 3.9, and mean duration of TNFi use was 1.5 years; 52.6% of patients had discontinued their first TNFi. Median time to loss of benefit was 29.2 months. 179 (55.1%) patients had persistent benefit at their previous clinic visit. An increased risk of losing clinical benefit was seen among patients with higher disease activity at discontinuation (CDAI≥3.2 vs <3.2; HR 1.43 (p=0.32)) and among smokers (HR 1.78 (p=0.027)). CONCLUSIONS: Patients with PsA who achieve LDA may maintain clinical benefit after discontinuation of TNFi therapy.
引用
- Huynh DH, Boyd TA, Etzel CJ, et al. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open. 2017. PMID: 28123783. doi:10.1136/rmdopen-2016-000395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。